Next-Generation Immunotherapies
In vivo CAR T and the Next Wave of Immune Reprogramming
5/13/2027 - May 14, 2027 ALL TIMES EDT
The ability to engineer therapeutic immune cells directly inside the body could transform how advanced immunotherapies are developed, manufactured, and delivered. With in vivo CAR T now generating early patient data and record investment from big pharma, Cambridge Healthtech Institute’s 6th Annual Next-Generation Immunotherapies conference will explore the technologies and translational strategies driving the field forward. The program will cover viral vectors, nanoparticles, mRNA, fusogens, and virus-like particles designed to target T cells, NK cells, myeloid cells, and hematopoietic stem cells. Key discussions will address biodistribution, transduction efficiency, genome integration, payload design, immune responses, cellular persistence, safety controls, and mitigation of CRS, neurotoxicity, and off target activity. Additional topics include CAR binder engineering, AI-assisted discovery, and in vivo expression of antibodies, T cell engagers, and multiple payloads.
Preliminary Agenda

PLENARY FIRESIDE CHAT

Panel Moderator:

PANEL DISCUSSION: From Discovery to Impact: Perspectives from a Patient Advocate and a Patient-Cohort Leader on Accelerating Therapeutic Innovation

Jane Osbourn, PhD, CEO, Alchemab Therapeutics Ltd. , CEO , Alchemab Therapeutics

Panelists:

Debra Miller, Founder & CEO, CureDuchenne , Founder & CEO , CureDuchenne

Craig Ritchie, PhD, CEO & Founder, Scottish Brain Sciences , Founder & CEO , Scottish Brain Sciences

LATEST DEVELOPMENTS IN IN VIVO CAR T

First-in-Human Experience with a Retargeted Lentiviral Vector for in vivo BCMA CAR T Generation

Photo of Stephen J Russell, MD, PhD, Executive Chairman and Chief Scientific Officer, Vyriad , Executive Chairman and Chief Scientific Officer , Vyriad
Stephen J Russell, MD, PhD, Executive Chairman and Chief Scientific Officer, Vyriad , Executive Chairman and Chief Scientific Officer , Vyriad

Transforming Immunotherapy through Multi-Immune Cell Programming in Vivo

Photo of Robert J. Hofmeister, PhD, CSO, CREATE Medicines , CSO , Create Medicines
Robert J. Hofmeister, PhD, CSO, CREATE Medicines , CSO , Create Medicines

All-RNA Safe-Harbor Integration for Redosable in vivo CAR T

Photo of Leanne Peiser, DPhil, CSO, Typewriter Therapeutics , Chief Scientific Officer , Typewriter Therapeutics
Leanne Peiser, DPhil, CSO, Typewriter Therapeutics , Chief Scientific Officer , Typewriter Therapeutics

Autologous CAR T cells have transformed hematological malignancy and more recently autoimmunity, but complex ex vivo manufacturing hinders access. In vivo CAR T addresses this, but transient mRNA and integrating viral formats have trade-offs in durability, redosing, and insertion-site control. The next evolution is non-viral integrating vectors. I will introduce our R2 retrotransposon approach for durable site-specific CAR integration from a tLNP-delivered all-RNA payload and update on our preclinical progress.

Writing the Future of Non-Viral Gene Insertion: All-RNA Stable in vivo CAR Therapies

Photo of Robert Mabry, PhD, CSO, Averna Therapeutics , CSO , Averna Therapeutics
Robert Mabry, PhD, CSO, Averna Therapeutics , CSO , Averna Therapeutics

Transient mRNA-based in vivo CAR approaches suffer short-lived expression, limiting CAR T persistence, expansion, and response depth, while durable alternatives rely on viral vectors or quasi-random integration risking oncogenicity. We present an all-RNA platform pairing R2 retrotransposon technology for single-site, safe-harbor CAR transgene writing with proprietary non-viral delivery offering CMC advantages. In vivo data demonstrate site-specific integration, durable expression, and profound potency, enabling stable, scalable, virus-free in vivo CAR therapy.

Escaping the Liver: Immunotropic LNPs for CD8 Targeted in vivo CAR T Engineering in Autoimmune Disease

Photo of Michael Klichinsky, PharmD, PhD, CSO, Nava Therapeutics , CSO , Nava Therapeutics
Michael Klichinsky, PharmD, PhD, CSO, Nava Therapeutics , CSO , Nava Therapeutics

In vivo CAR T cell therapy has the potential to enable immune reset and durable responses in autoimmune disease. Advances in targeted delivery are creating new opportunities for potent, selective, and well-tolerated engineering of T cells directly within the body. This talk will highlight progress at Nava Therapeutics toward realizing the promise of in vivo CAR T therapy.

In vivo Genome Editing Enables Site-Specific Integration for TRAC-CAR T Cell Generation

Photo of Connor Tsuchida, PhD, Vice President, R&D, Azalea Therapeutics , Vice President , Research & Development , Azalea Therapeutics
Connor Tsuchida, PhD, Vice President, R&D, Azalea Therapeutics , Vice President , Research & Development , Azalea Therapeutics

Panel Moderator:

PANEL DISCUSSION:
Advancing the Field of in vivo Engineering

Adrian Bot, MD, PhD, Former CSO, Executive Vice President, R&D, Capstan Therapeutics , Chief Scientific Officer & Executive Vice President , R&D , Capstan Therapeutics

Panelists:

John Rossi, PhD, Senior Vice President, Stealth Co.; Former Vice President, Translational Medicine, Capstan Therapeutics , Vice President , Translational Medicine , Capstan Therapeutics

Jagesh V. Shah, PhD, Senior Vice President, Head of Platform, Mirai Bio , Senior Vice President, Head of Platform , Stealth Startup (Flagship Pioneering)

MRNA-ENCODED T CELL ENGAGERS

mRNA-Encoded T Cell Engagers for the Treatment of Autoimmune Diseases

Photo of Bo Ying, PhD, CEO, Abogen Biosciences Co. Ltd. , CEO , Abogen Biosciences Co., Ltd.
Bo Ying, PhD, CEO, Abogen Biosciences Co. Ltd. , CEO , Abogen Biosciences Co., Ltd.

This presentation explores the development of mRNA-encoded T-cell engagers (TCEs) as a novel therapeutic modality for autoimmune diseases. We will discuss advanced LNP delivery systems, platform design strategies, and translational insights from our pioneering clinical programs targeting B-cell-driven pathologies.

In vivo mRNA-Encoded TCEs

Photo of Wei Xu, PhD, CSO, METiS TechBio , CSO , METiS TechBio
Wei Xu, PhD, CSO, METiS TechBio , CSO , METiS TechBio

T cell engagers (TCEs) are limited by suboptimal pharmacokinetics and safety. We present an mRNA-LNP platform enabling in vivo expression of bispecific and trispecific TCEs with tunable exposure and tissue-directed activity. Through mRNA sequence and formulation engineering, this approach achieves potent efficacy with improved safety and reduced cytokine release compared to recombinant formats. Preclinical data highlight its potential to expand the therapeutic window in oncology and autoimmunity.

T Cell Activation-Coupled Transduction (TACT) Platform for in vivo TCR-T Engineering

Photo of Hongming Hu, PhD, Head, ImmuXell , Head , Pharmaessentia Shanghai
Hongming Hu, PhD, Head, ImmuXell , Head , Pharmaessentia Shanghai

TACT (T cell activation-coupled transduction) uses a stable retroviral producer platform to generate RD114-pseudotyped vectors. TACT enables single-step T cell activation and transduction, generating KRAS G12V-specific TCR-T cells in vivo with superior serum stability versus VSV-G–pseudotyped lentiviral vectors. In PBMC-humanized pancreatic cancer mice, one intravenous dose produced dose-dependent antitumor activity. Preclinical assessments showed T cell-restricted transduction, rapid vector clearance, no elevation of CRS-associated cytokines, and no histopathologic organ toxicity.


TARGETED DELIVERY, GENOME ENGINEERING, AND NEW FRONTIERS

AI-Driven Development of Nanoparticles for in vivo Immune-Cell Delivery

Photo of Bowen Li, PhD, Assistant Professor, Pharmaceutical Sciences, University of Toronto , Assistant Professor , Pharmaceutical Sciences , University of Toronto
Bowen Li, PhD, Assistant Professor, Pharmaceutical Sciences, University of Toronto , Assistant Professor , Pharmaceutical Sciences , University of Toronto

Organ-Tropic LNP-Based Engineering of T Cells for Solid Cancer Treatment

Photo of Daniel J. Powell Jr., PhD, Professor, Pathology & Laboratory Medicine, University of Pennsylvania , Professor , Pathology & Laboratory Medicine , University of Pennsylvania
Daniel J. Powell Jr., PhD, Professor, Pathology & Laboratory Medicine, University of Pennsylvania , Professor , Pathology & Laboratory Medicine , University of Pennsylvania

Organ-tropic lipid nanoparticles (LNPs) offer a potential strategy for delivering therapeutic payloads to T cells within specific tissues. This presentation will explore LNP-based approaches to T cell engineering for solid cancer treatment, highlighting how nanoparticle design and biodistribution may influence delivery and antitumor activity. Discussion will consider opportunities to enhance tissue targeting and therapeutic responses, alongside challenges in achieving cellular selectivity, evaluating safety, and translating these strategies into clinical applications.

In vivo CAR T Cell Generation Using Lentivirus with Novel Viral Fusogens

Photo of Robert T. Manguso, PhD, Principal Investigator, TIDE Project, Broad Institute , Principal Investigator , TIDE Project , Broad Institute
Robert T. Manguso, PhD, Principal Investigator, TIDE Project, Broad Institute , Principal Investigator , TIDE Project , Broad Institute

We describe pseudotyped lentiviral vectors engineered for efficient, selective delivery to human T cells. Chimeric dolphin morbillivirus envelope glycoproteins enable targeted infection while evading neutralization by measles-vaccinated human serum. Camelid-derived nanobodies improve retargeting compared with single-chain variable fragment antibodies. CD7-targeted vectors demonstrate efficient, highly specific human T cell infection in vitro and in vivo, generating functional CAR T cells and achieving therapeutic efficacy in a preclinical B cell lymphoma model.

Reprogramming Brain Tumor Immunity In Situ: Overcoming Resistance to CAR-Based Therapies with Next-Generation Immune Engineering

Eric P Grewal, Instructor & Physician Investigator, Neurosurgery, Massachusetts General Hospital , Instructor & Physician Investigator , Neurosurgery , Massachusetts General Hospital

Despite early clinical activity, CAR T cell therapies for glioma remain limited by antigen heterogeneity, metabolic immune suppression, and a profoundly immunosuppressive tumor microenvironment. Drawing on translational studies of glioma immunobiology and emerging in vivo CAR technologies, this presentation examines how advances in immune-cell engineering and delivery platforms could help overcome these barriers. We will explore the biological rationale, emerging preclinical and clinical evidence, and challenges for translating in vivo immunotherapies into effective treatments for brain tumors


For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute
Phone: +44 7837 651 303
Email: dbarry@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: +1 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: +1 781-972-1340
Email: ashleyparsons@healthtech.com


Register

View By:


Premier Sponsors

Biointron_new       Kactus